Quénet F, Carrère S, Sgarbura O [Contribution of intraperitoneal chemotherapy in the treatment of colorectal peritoneal carcinoma. HIPEC, PIPAC, state of the art and future directions]. Bull Cancer. 2024-02-07. doi:10.1016/j.bulcan.2023.10.006
Trecourt A, Bakrin N, Glehen O, Gertych W, Villeneuve L, Isaac S, Benzerdjeb N, Fontaine J, Genestie C, Dartigues P, Leroux A, Odin C, Khellaf L, Svrcek M, Thierry S, Augros M, Omar A, Devouassoux-Shisheboran M, Kepenekian V Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study. Ann Surg Oncol. 2024-02-10. doi:10.1245/s10434-023-14850-0
Trecourt A, Bakrin N, Glehen O, Gertych W, Villeneuve L, Isaac S, Benzerdjeb N, Fontaine J, Genestie C, Dartigues P, Leroux A, Odin C, Khellaf L, Svrcek M, Thierry S, Augros M, Omar A, Devouassoux-Shisheboran M, Kepenekian V ASO Visual Abstract: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study. Ann Surg Oncol. 2024-02-09. doi:10.1245/s10434-024-14925-6
Desroys du Roure P, Lajoie L, Mallavialle A, Alcaraz L, Mansouri H, Fenou L, Garambois V, Rubio L, David T, Coenon L, Boissière-Michot F, Chateau M-C, Ngo G, Jarlier M, Villalba M, Martineau P, Laurent-Matha V, Roger P, Guiu S, Chardès T, Gros L, Liaudet-Coopman E A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. J Immunother Cancer. 2024;12(1):e007135. doi:10.1136/jitc-2023-007135
Roussel-Simonin C, Croce S, Guyon F, Llacer C, Ray-Coquard I, Meeus P, Genestie C, Malhaire C, Duffaud F, Pautier P [Uterin sarcoma, high-grade stroma, indifferenciated, referential]. Bull Cancer. 2023;110(7-8):855-864. doi:10.1016/j.bulcan.2023.03.017
Alexandre M, Jacot W [Therapeutic advances in HER2+ breast cancer]. Rev Prat. 2023;73(4):355-359.
Belkacemi Y, Debbi K, Besnard C, Grellier N, Fonteneau G, Colson-Durand L, Lerouge D, Durdux C, Campana F, Pons P, Flandin I, Pasquier D, de Crevoisier R, Wachter T, Thureau S, Conzague-Casabianca L, Petit A, Supiot S, Azria D [The morbidity and mortality review meetings in radiotherapy departments: Procedure, implementation and prospects of the "Proust" French national project]. Cancer Radiother. 2023;27(6-7):474-479. doi:10.1016/j.canrad.2023.06.018
Marguerit A, Azria D, Riou O, Demontoy S, Thezenas S, Boisselier P [Stereotactic Body Radiation Therapy for less than 3cm (stage I) and 5cm (stage II) inoperable lung tumors: 10 years experience of Montpellier Cancer Institute]. Cancer Radiother. 2023;27(5):387-397. doi:10.1016/j.canrad.2023.05.002
Bourgier C, Boisbouvier S, Bayart É, Chamois J, Clavère P, Corbin S, De Oliveira A, Hannoun-Lévi J-M, Hasbini A, Geffroy-Hulot C, Le Tallec P, Monpetit É, Santini J-J [Radiation therapists shortage in France: Organizational consequences and difficulties in deploying new missions and/or tasks delegation]. Cancer Radiother. 2023;27(6-7):577-582. doi:10.1016/j.canrad.2023.07.007
Hanslik N, Bourgier C, Thezenas S, Firmin N, Riou O, Azria D, Llacer-Moscardo C [Predictive factors assessment of pathological response to neoadjuvant radiotherapy of soft tissue sarcomas]. Cancer Radiother. 2023-10-07. doi:10.1016/j.canrad.2023.02.003
Quesada S, Solassol J, Ray-Coquard I, Fabbro M [Homologous recombination deficiency in epithelial ovarian cancers: from molecular characterization to patient journey]. Bull Cancer. 2023;110(4):371-381. doi:10.1016/j.bulcan.2023.02.004
Legouté F, Lesueur P, El Kabbaj O, Ghannam Y, Michalet M, Monpetit E, Azria D, Giraud P, Calais G, Pointreau Y, Ollivier L [French careers in oncology radiotherapy: Crossing views]. Cancer Radiother. 2023;27(1):75-79. doi:10.1016/j.canrad.2022.07.016
Bollet M, Racadot S, Rivera S, Arnaud A, Bourgier C [Breast cancer radiation therapy: Current questions in 2023]. Cancer Radiother. 2023;27(6-7):524-530. doi:10.1016/j.canrad.2023.07.005
Bruneaux E, Iborra F, Trouche-Sabatier S, Foucan A, Gras-Aygon C, Poinas G, Azria D, Trétarre B [Bladder tumors in the Hérault department: Results of the Hérault tumor registry registration from1987 to 2019]. Prog Urol. 2023-08-28. doi:10.1016/j.purol.2023.08.015
Bay J-O, Bouleuc C, Caux C, Delom F, Firmin N, Gandemer V, L'Allemain G, Orbach D, Robert J, Rodrigues M, Sabatier R, Thiery-Vuillemin A, Wislez M [A 2022 inventory in oncology news]. Bull Cancer. 2023;110(1):19-31. doi:10.1016/j.bulcan.2022.12.002
What is the role of the neutrophil extracellular traps in the cardiovascular disease burden associated with hemodialysis bioincompatibility?. Frontiers. 2023;10. doi:10.3389/fmed.2023.1268748
Yeh C, Zhou M, Sigel K, Jameson G, White R, Safyan R, Saenger Y, Hecht E, Chabot J, Schreibman S, Ychou M, Conroy T, Fojo T, Manji G, Von Hoff D, Bates S Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. Oncologist. 2023;28(2):139-148. doi:10.1093/oncolo/oyac217
Faravel K, Jarlier M, Senesse P, Huteau M-E, Janiszewski C, Stoebner A, Boisselier P Trismus Occurrence and Link With Radiotherapy Doses in Head and Neck Cancer Patients Treated With Chemoradiotherapy. Integr Cancer Ther. 2023;22. doi:10.1177/15347354221147283
Hurvitz S, Hegg R, Chung W-P, Im S-A, Jacot W, Ganju V, Chiu J, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning J-W, Curigliano G, Perez-Garcia J, Kim S-B, Petry V, Huang C-S, Li W, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105-117. doi:10.1016/S0140-6736(22)02420-5
Sargos P, Le Guevelou J, Khalifa J, Albiges L, Azria D, de Crevoisier R, Supiot S, Créhange G, Roubaud G, Chapet O, Pasquier D, Blanchard P, Latorzeff I The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer Radiother. 2023-06-05. doi:10.1016/j.canrad.2023.02.004
Shoji K, Bayet E, Leverrier-Penna S, Le Devedec D, Mallavialle A, Marionneau-Lambot S, Rambow F, Perret R, Joussaume A, Viel R, Fautrel A, Khammari A, Constantin B, Tartare-Deckert S, Penna A The mechanosensitive TRPV2 calcium channel promotes human melanoma invasiveness and metastatic potential. EMBO Rep. 2023-02-06. doi:10.15252/embr.202255069
Aristei C, Kaidar-Person O, Boersma L, Leonardi M, Offersen B, Franco P, Arenas M, Bourgier C, Pfeffer R, Kouloulias V, Bölükba?? Y, Meattini I, Coles C, Luis A, Masiello V, Palumbo I, Morganti A, Perrucci E, Tombolini V, Krengli M, Marazzi F, Trigo L, Borghesi S, Ciabattoni A, Rato?a I, Valentini V, Poortmans P The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer. Crit Rev Oncol Hematol. 2023;187. doi:10.1016/j.critrevonc.2023.104035
Danieli R, Pistone D, Tranel J, Botta F, Uribe?Munoz C, Raspanti D, Salvat F, Wilderman S, Bardiès M, Amato E, Dewaraja Y, Cremonesi M Technical note: Impact of dose voxel kernel (DVK) values on dosimetry estimates in 177 Lu and 90 Y radiopharmaceutical therapy (RPT) applications. Medical Physics. 2023-09-15. doi:10.1002/mp.16729
Mailliez A, Lusque A, Caron O, Cabel L, Goncalves A, Debled M, Gladieff L, Ferrero J-M, Petit T, Mouret-Reynier M, Eymard J-C, Levy C, Uwer L, Leheurteur M, Desmoulins I, Bachelot T, Simon G, Jacot W, Delaloge S Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. Int J Cancer. 2023;152(5):921-931. doi:10.1002/ijc.34304
Bordeau K, Michalet M, Keskes A, Valdenaire S, Debuire P, Cantaloube M, Cabaillé M, Jacot W, Draghici R, Demontoy S, Quantin X, Ychou M, Assenat E, Mazard T, Gauthier L, Dupuy M, Guiu B, Bourgier C, Fenoglietto P, Azria D, Riou O Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study. J Clin Med. 2023;12(3):1183. doi:10.3390/jcm12031183
Institut de Recherche en Cancérologie de
